Patent Assignment
Reel/Frame 030187/0309
Change of Name
Recorded: 2013-04-10
Pages: 5
Assignor
MICROMET AG
Executed: 2012-03-08
Assignee
AMGEN RESEARCH (MUNICH) GMBH
STAFFELSEESTRASSE 2, MUNICH, 81477, GERMANY
Covered Properties
(25)
Cd 19XCD3 Specific Polypeptides and Uses Thereof
Patent:
7,112,324 →
Application:
09/673,735 →
Pharmaceutical Composition Comprising a Bispecific Antibody for Epcam
Pharmaceutical Compositions Comprising Bispecific Anti-CD3, Anti-CD19 Antibody Constructs for the Treatment of B-Cell Related Disorders
Multispecific Deimmunized CD3-Binders
Less Immunogenic Binding Molecules
Novel CD19XCD3 Specific Polypeptides and Uses Thereof
Composition Comprising Cross-Species-Sepecific Antibodies and Uses Thereof
Means and Methods for the Treatment of Tumorous Diseases
Pharmaceutical Compositions with Resistance to Soluble Cea
Cross-Species-Specific Binding Domain
Application:
12/594,713 →
Publication:
US 2010/0150918
CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
Application:
13/122,242 →
Publication:
US 2012/0034228
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
Application:
13/122,245 →
Publication:
US 2011/0293619
Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens
Cross-Species-Specific Single Domain Bispecific Single Chain Antibody
Treatment of Pediatric Acute Lymphoblastic Leukemia
Application:
13/127,538 →
Publication:
US 2011/0262440
Treatment of Acute Lymphoblastic Leukemia
Application:
13/127,541 →
Publication:
US 2013/0323247
Means and Methods for the Treament of B Cell Non-Hodgkin Lymphoma and B Cell Leukemia
Multispecific Deimmunized CD3-Binders
Pharmaceutical Antibody Compositions with Resistance to Soluble Cea
Cross-Species-Specific Bispecific Binders
Application:
13/408,363 →
Publication:
US 2012/0244162
DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
Application:
13/496,836 →
Publication:
US 2012/0244161
Dosage Regimen for Administering a CD19XCD3 Bispecific Antibody
Compositions Comprising Cross-Species-Specific Antibodies and Uses Thereof
Application:
13/567,672 →
Publication:
US 2013/0129729
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
Pharmaceutical Compositions with Resistance to Soluble Cea
Related Assignments
(8)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 12, 2011
From: ZUGMAIER, GERHARD
To: MICROMET AG
Reel/Frame 026270/0836 →
Assignment of Assignor's Interest
May 12, 2011
From: ZUGMAIER, GERHARD; DEGENHARD, EVELYN
To: MICROMET AG
Reel/Frame 026270/0920 →
Assignment of Assignor's Interest
Jul 15, 2011
From: KUFER, PETER; BLUMEL, CLAUDIA; KISCHEL, ROMAN
To: MICROMET AG
Reel/Frame 026600/0447 →
Assignment of Assignor's Interest
Jul 15, 2011
From: KUFER, PETER; RAUM, TOBIAS; KISCHEL, ROMAN; MANGOLD, SUSANNE
To: MICROMET AG
Reel/Frame 026600/0557 →
Assignment of Assignor's Interest
Jul 28, 2011
From: KUFER, PETER; RAUM, TOBIAS
To: MICROMET AG
Reel/Frame 026666/0070 →
Assignment of Assignor's Interest
Jul 28, 2011
From: KUFER, PETER; RAUM, TOBIAS; KISCHEL, ROMAN; LUTTERBUSE, RALF
To: MICROMET AG
Reel/Frame 026665/0748 →
Change of Name
Apr 12, 2013
From: MICROMET AG
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 030208/0849 →
Assignment of Assignor's Interest
Feb 19, 2021
From: KISCHEL, ROMAN; LUTTERBÜSE, RALF; HOFFMANN, PATRICK; KLINGER, MATTHIAS
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 055345/0495 →